METHODS OF TREATMENT FOR ULCERATIVE COLITIS
Disclosed herein are new treatments for moderate ulcerative colitis in various subject subgroups. The various subject subgroups include Caucasians, non-smokers, subjects under the age of about 65 years, and subjects previously or currently being treated with steroids.
1 . A method of treating moderate ulcerative colitis in a mammalian subject comprising he step of administering to said mammalian subject an aminosalicylate in an amount to deliver to said subject more than about 2.4 g/day of 5-aminosalicylic acid, wherein said mammalian subject is selected from the group consisting of:
human subjects under about 65 years of age,
Caucasian human subjects,
non-smoking human subjects; and,
previous or current steroid-using mammalian subjects.
2 . The method of claim 1 , wherein the mammalian subject is a human.
3 . The method of claim 2 , wherein said step of administering an aminosalicylate comprises orally administering an aminosalicylate in an amount to deliver less than about 4.8 g/day of 5-aminosalicylic acid to said subject.
4 . The method of claim 3 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
5 . The method of claim 3 , wherein said step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day.
6 . The method of claim 2 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
7 . The method of claim 6 , wherein said aminosalicylate comprises mesalamine and further wherein said mesalamine is administered in an amount of about 4.8 g/day.
8 . The method of claim 2 , wherein said step of orally administering comprises orally administering a tablet comprising about 800 milligrams of mesalamine or a salt thereof.
9 . The method of claim 8 , wherein said tablet is a delayed-release tablet.
10 . The method of claim 2 , wherein said aminosalicylate comprises a component selected from the group consisting of mesalmine, salts of mesalamine, olsalazine, salts of olsalazine, balsalazide, salts of balsalazide, sulfasalazine, salts of sulfasalazine, and combinations thereof.
11 . The method of claim 2 , wherein said step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day.
12 . The method of claim 2 , wherein the human subject is under about 65 years of age.
13 . The method of claim 2 , wherein the human subject is Caucasian.
14 . The method of claim 2 , wherein the human subject is a non-smoking human subject.
15 . The method of claim 2 , wherein the human subject is a previous or current steroid user.
16 . The method of claim 2 , wherein the step of administering comprises rectal administration.
17 . The method of claim 16 , wherein said step of administering an aminosalicylate comprises administering an aminosalicylate in an amount to deliver about 4.8 g/day of 5-aminosalicylic acid to said subject.
18 . The method of claim 17 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
19 . The method of claim 18 , wherein said step of administering comprises administering once per day, twice per day, three times per day, or four times per day.
20 . The method of claim 16 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
21 . The method of claim 16 , wherein said aminosalicylate comprises mesalamine and further wherein said mesalamine is administered in an amount of about 4.8 g/day.
22 . The method of claim 16 , wherein said step of administering comprises administering a rectal composition comprising about 800 milligrams or about 1.2 g of mesalamine or a salt thereof.
23 . The method of claim 16 , wherein said rectal composition is an enema.
24 . The method of claim 16 , wherein said rectal composition is a foam.
25 . The method of claim 16 , wherein said aminosalicylate comprises a component selected from the group consisting of mesalamine, salts of mesalamine, olsalazine, salts of olsalazine, balsalazide, salts of balsalazide, sulfasalazine, salts of sulfasalazine, and combinations thereof.
26 . The method of claim 16 , wherein said step of administering comprises administering once per day, twice per day, three times per day, or four times per day.
27 . The method of claim 16 , wherein the human subject is under about 65 years of age.
28 . The method of claim 16 , wherein the human subject is Caucasian.
29 . The method of claim 16 , wherein the human subject is a non-smoking human subject.
30 . The method of claim 16 , wherein the human subject is a previous or current steroid user.